Webinar

Virtual 21st Annual Pharmaceutical and Medical Device Compliance Congress: Mini Summit VIII

Wednesday, November 04 11:15 AM EDT to 12:15 PM EDT

PCF’s annual International Pharmaceutical Compliance Congress is one of the premier events for compliance and legal professionals in the bio/pharma industry worldwide. This year, Life Sciences Consulting Group Leaders, BJ D’Avella will participate on a panel focusing on compliance considerations for rare and ultra-rare drugs.
Mini Summit VIII: Compliance Considerations for Rare and Ultra Rare Drugs

Join the discussion on key compliance considerations for rare and ultra-rare products related to the following areas:

• Disease State Education

• Patient Interactions

• HCP Engagement

• Medical/Commercial Interactions

Speakers:

BJ D’Avella, MBA
Leader, Life Sciences Consulting Group, Paul Hastings, New York, NY (Moderator)

• Terra Buckley, JD
  Vice President, Head of Global Compliance, Mesoblast Limited; Former Executive Director, Head of the Business Advisory Center of Excellence, US Healthcare Compliance, Celgene; New York, NY

• Mark P. Graves, JD, MBA
  Senior Vice President and Chief Compliance Officer, MiMedx Group; Former Senior Director, Office of Ethics and Compliance, Abbott Laboratories; Former Deputy Ethics & Compliance Officer, Takeda Pharmaceuticals; Marietta, GA

• Gregory S. Moss, LLB
  Executive Vice President, General Counsel and Corporate Secretary, Chief Compliance Officer, Kadmon Holdings, New York, NY

• Jennifer Santos, JD
  Senior Director, R&D Business Partner, Office of Business Integrity & Ethics, Vertex Pharmaceuticals, Boston, MA

For more information and to register, click here  to visit the conference website.